Kellerhals Carrard SA acted as legal advisor to Amazentis in this transaction.
Amazentis, an EPFL spin-off founded by Prof. Patrick Aebischer, has announced that it is entering into a strategic partnership with Nestlé Health Science.
This partnership supports Nestlé’s pursuit of growth opportunities both in consumer healthcare and medical nutrition. Nestlé Health Science will take an equity stake in Amazentis and receive global rights to use Amazentis’ patented Urolithin A technology for dietary supplements, select foods and beverages, and medical nutrition products. Amazentis retains co-exclusive rights for the online distribution of dietary supplements and select food products as well as global exclusive rights for distribution of certain other defined categories.
Nestlé Health Science and Amazentis will also conduct a joint research program to expand applications of Urolithin A into new consumer health and medical benefit areas.
Urolithin A is a bioactive dietary metabolite that is naturally produced when eating certain foods, such as the pomegranate, though it is difficult for most people to get enough of this specialized nutrient from food alone. Urolithin A is the first natural bioactive to improve mitochondrial function by activating mitophagy, a process by which aging and damaged mitochondria are cleared from the cell. Optimal mitochondrial function is central to cell metabolism and overall health. This is part of a new class of nutrients, called cellular nutrients, which go beyond traditional macro and micronutrients and are clinically proven to improve cellular health.
Kellerhals Carrard acted as legal advisor to Amazentis in this transaction with a team led by Jean-Luc Chenaux (picture), partner, Stéphane Manaï, senior associate and Joséphine Marmy, associate.
Law Firms: Kellerhals Carrard;
Clients: Amazentis SA;